Roche reports positive Phase III trial results of lymphoma drug Gazyva
An independent data monitoring committee determined that the open-label, multicenter, randomized two-arm trial met its primary endpoint early. Roche chief medical officer and head of Global Product Development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.